{"transactions":[{"id":724106,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:38:30.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":5.5,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-26-000305","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000305/form4.xml","form_type":"4"}},{"id":724392,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34867,"kind":"person","name":"Chavez Margarita","position":1,"cik":"0002032496","reported_name":"Chavez Margarita","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:37:59.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":5.5,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-26-000304","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032496/000161071726000304/form4.xml","form_type":"4"}},{"id":724103,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34837,"kind":"person","name":"Martell Bridget A","position":1,"cik":"0001629627","reported_name":"Martell Bridget A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:37:30.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":5.5,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-26-000303","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000303/form4.xml","form_type":"4"}},{"id":724102,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:36:56.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":5.5,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-26-000302","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000302/form4.xml","form_type":"4"}},{"id":724101,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:36:27.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":5.5,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-26-000301","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000301/form4.xml","form_type":"4"}},{"id":724124,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:35:55.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":5.5,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-26-000300","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813780/000161071726000300/form4.xml","form_type":"4"}},{"id":848771,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-11T20:19:59.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":23310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":23310,"derivative":{"exercise_price":7.03,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":23310},"source":{"system":"sec-edgar","filing":"0001610717-26-000095","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000095/form4.xml","form_type":"4"}},{"id":848770,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61516,"kind":"person","name":"Aneja Nikhil","position":1,"cik":"0002112438","reported_name":"Aneja Nikhil","relationship":{"officer":true,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-11T20:14:00.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":9450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":9450,"derivative":{"exercise_price":7.03,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":9450},"source":{"system":"sec-edgar","filing":"0001610717-26-000094","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000094/form4.xml","form_type":"4"}},{"id":848769,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-11T20:13:30.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":37485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":37485,"derivative":{"exercise_price":7.03,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":37485},"source":{"system":"sec-edgar","filing":"0001610717-26-000093","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000093/form4.xml","form_type":"4"}},{"id":848764,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-11T20:13:06.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":105840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":105840,"derivative":{"exercise_price":7.03,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":105840},"source":{"system":"sec-edgar","filing":"0001610717-26-000092","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000092/form4.xml","form_type":"4"}},{"id":1084743,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-18T21:14:30.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":179800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":179800,"derivative":{"exercise_price":8.68,"expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":179800},"source":{"system":"sec-edgar","filing":"0001610717-25-000290","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000290/form4.xml","form_type":"4"}},{"id":1084742,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-18T21:14:05.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":16000,"derivative":{"exercise_price":8.68,"expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001610717-25-000289","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000289/form4.xml","form_type":"4"}},{"id":1084741,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-18T20:41:45.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":40185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":40185,"derivative":{"exercise_price":8.68,"expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":40185},"source":{"system":"sec-edgar","filing":"0001610717-25-000286","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000286/form4.xml","form_type":"4"}},{"id":1101099,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-26T20:31:16.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":7.63,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-25-000259","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000259/form4.xml","form_type":"4"}},{"id":1101097,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-26T20:30:56.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":7.63,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-25-000258","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000258/form4.xml","form_type":"4"}},{"id":1101104,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-26T20:30:36.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":7.63,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-25-000257","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813780/000161071725000257/form4.xml","form_type":"4"}},{"id":1101098,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-26T20:30:19.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":7.63,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-25-000256","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000256/form4.xml","form_type":"4"}},{"id":1101196,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34867,"kind":"person","name":"Chavez Margarita","position":1,"cik":"0002032496","reported_name":"Chavez Margarita","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-26T20:29:46.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":7.63,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-25-000255","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032496/000161071725000255/form4.xml","form_type":"4"}},{"id":1101096,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34837,"kind":"person","name":"Martell Bridget A","position":1,"cik":"0001629627","reported_name":"Martell Bridget A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-26T20:29:23.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":7.63,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-25-000254","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000254/form4.xml","form_type":"4"}},{"id":1228997,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:33:51.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":140103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":140103,"derivative":{"exercise_price":16.87,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":140103},"source":{"system":"sec-edgar","filing":"0001610717-25-000046","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000046/form4.xml","form_type":"4"}},{"id":1228996,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:33:20.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":21693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":21693,"derivative":{"exercise_price":16.87,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":21693},"source":{"system":"sec-edgar","filing":"0001610717-25-000045","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000045/form4.xml","form_type":"4"}},{"id":1228995,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:32:51.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":47271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":47271,"derivative":{"exercise_price":16.87,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":47271},"source":{"system":"sec-edgar","filing":"0001610717-25-000044","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000044/form4.xml","form_type":"4"}},{"id":1388226,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":86859,"kind":"person","name":"Achneck Hardean","position":1,"cik":"0002037976","reported_name":"Achneck Hardean","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-10T16:16:11.000Z","date":"2024-10-08","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty Five Percent (25%) of the shares subject to the option will vest on September 23, 2025 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":7.32,"expiration_date":"2034-10-08","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001610717-24-000503","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037976/000161071724000503/form4.xml","form_type":"4"}},{"id":1412781,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T20:23:49.000Z","date":"2024-09-04","kind":"grant","planned":false,"acquired":true,"shares":10880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":10880,"derivative":{"exercise_price":11.74,"expiration_date":"2034-09-04","underlying":"Common Stock","underlying_shares":10880},"source":{"system":"sec-edgar","filing":"0001610717-24-000466","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000466/form4.xml","form_type":"4"}},{"id":1412780,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T20:23:18.000Z","date":"2024-09-04","kind":"grant","planned":false,"acquired":true,"shares":33920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":33920,"derivative":{"exercise_price":11.74,"expiration_date":"2034-09-04","underlying":"Common Stock","underlying_shares":33920},"source":{"system":"sec-edgar","filing":"0001610717-24-000465","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000465/form4.xml","form_type":"4"}},{"id":1412779,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T20:22:44.000Z","date":"2024-09-04","kind":"grant","planned":false,"acquired":true,"shares":10880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":10880,"derivative":{"exercise_price":11.74,"expiration_date":"2034-09-04","underlying":"Common Stock","underlying_shares":10880},"source":{"system":"sec-edgar","filing":"0001610717-24-000464","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000464/form4.xml","form_type":"4"}},{"id":1437082,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34867,"kind":"person","name":"Chavez Margarita","position":1,"cik":"0002032496","reported_name":"Chavez Margarita","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-09T20:09:21.000Z","date":"2024-08-07","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the total number of shares vest in thirty-six (36) successive and equal monthly installments measured from August 7, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":120000,"derivative":{"exercise_price":0.55,"expiration_date":"2034-08-07","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001610717-24-000423","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032496/000161071724000423/form4.xml","form_type":"4"}},{"id":1436936,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34839,"kind":"person","name":"Preston Heather","position":1,"cik":"0001606826","reported_name":"Preston Heather","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-09T20:08:56.000Z","date":"2024-08-07","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the total number of shares vest in thirty-six (36) successive and equal monthly installments measured from August 7, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":120000,"derivative":{"exercise_price":0.55,"expiration_date":"2034-08-07","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001610717-24-000422","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000422/form4.xml","form_type":"4"}},{"id":1467297,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:08:43.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":0.38,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001610717-24-000372","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813780/000161071724000372/form4.xml","form_type":"4"}},{"id":1467281,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:08:13.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":0.38,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001610717-24-000371","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000371/form4.xml","form_type":"4"}},{"id":1467280,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:07:46.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":0.38,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001610717-24-000370","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000370/form4.xml","form_type":"4"}},{"id":1467279,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34837,"kind":"person","name":"Martell Bridget A","position":1,"cik":"0001629627","reported_name":"Martell Bridget A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:07:03.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":0.38,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001610717-24-000369","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000369/form4.xml","form_type":"4"}},{"id":1603386,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T22:42:56.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":308940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":308940,"derivative":{"exercise_price":1.13,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":308940},"source":{"system":"sec-edgar","filing":"0001610717-24-000123","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000123/form4.xml","form_type":"4"}},{"id":1603385,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T22:42:19.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":72000,"derivative":{"exercise_price":1.13,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001610717-24-000122","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000122/form4.xml","form_type":"4"}},{"id":1603384,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T22:41:28.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":965435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":965435,"derivative":{"exercise_price":1.13,"expiration_date":"2024-03-01","underlying":"Common Stock","underlying_shares":965435},"source":{"system":"sec-edgar","filing":"0001610717-24-000121","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000121/form4.xml","form_type":"4"}},{"id":1603654,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T17:44:26.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":72000,"derivative":{"exercise_price":1.13,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0001610717-24-000124","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000124/form4.xml","form_type":"4"}},{"id":1612511,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:35:02.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":4411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":4411,"derivative":{"exercise_price":0.96,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":4411},"source":{"system":"sec-edgar","filing":"0001610717-24-000102","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813780/000161071724000102/form4.xml","form_type":"4"}},{"id":1612510,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:35:02.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":26.58,"exercise_date":"2022-06-17","expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000102","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813780/000161071724000102/form4.xml","form_type":"4"}},{"id":1612481,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:34:29.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":8823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on April 26, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":8823,"derivative":{"exercise_price":0.96,"expiration_date":"2031-04-26","underlying":"Common Stock","underlying_shares":8823},"source":{"system":"sec-edgar","filing":"0001610717-24-000101","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000101/form4.xml","form_type":"4"}},{"id":1612480,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:34:29.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on April 26, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":29.1,"exercise_date":"2021-05-26","expiration_date":"2031-04-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001610717-24-000101","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000101/form4.xml","form_type":"4"}},{"id":1612479,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:48.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":18750,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001610717-24-000099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000099/form4.xml","form_type":"4"}},{"id":1612478,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:48.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":74998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date."}],"balance_after":74998,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":74998},"source":{"system":"sec-edgar","filing":"0001610717-24-000099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000099/form4.xml","form_type":"4"}},{"id":1612477,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:48.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":51833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 176,237 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 51,833 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":51833,"derivative":{"exercise_price":0.96,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":51833},"source":{"system":"sec-edgar","filing":"0001610717-24-000099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000099/form4.xml","form_type":"4"}},{"id":1612476,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:48.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2025-02-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":26250},"source":{"system":"sec-edgar","filing":"0001610717-24-000099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000099/form4.xml","form_type":"4"}},{"id":1612475,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:48.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2022-03-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001610717-24-000099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000099/form4.xml","form_type":"4"}},{"id":1612474,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:48.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":176237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 176,237 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 51,833 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":16.18,"exercise_date":"2021-01-01","expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":176237},"source":{"system":"sec-edgar","filing":"0001610717-24-000099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000099/form4.xml","form_type":"4"}},{"id":1612473,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":57749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,850 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 57,749 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":57749,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":57749},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612472,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":230999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 323,400 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 230,999 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date."}],"balance_after":230999,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":230999},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612471,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":132352,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 450,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 132,352 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":132352,"derivative":{"exercise_price":0.96,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":132352},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612470,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,850 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 57,749 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2025-02-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":80850},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612469,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":323400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 323,400 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 230,999 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2022-03-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":323400},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612468,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 450,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 132,352 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":16.18,"exercise_date":"2021-01-01","expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612467,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:31:16.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":18750,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001610717-24-000097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000097/form4.xml","form_type":"4"}},{"id":1612466,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:31:16.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":74998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date."}],"balance_after":74998,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":74998},"source":{"system":"sec-edgar","filing":"0001610717-24-000097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000097/form4.xml","form_type":"4"}},{"id":1612465,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:31:16.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":58822,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 200,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 58,822 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":58822,"derivative":{"exercise_price":0.96,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":58822},"source":{"system":"sec-edgar","filing":"0001610717-24-000097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000097/form4.xml","form_type":"4"}},{"id":1612464,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:31:16.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2025-02-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":26250},"source":{"system":"sec-edgar","filing":"0001610717-24-000097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000097/form4.xml","form_type":"4"}},{"id":1612463,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:31:16.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2022-03-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001610717-24-000097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000097/form4.xml","form_type":"4"}},{"id":1612462,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:31:16.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 200,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 58,822 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":16.18,"exercise_date":"2021-01-01","expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001610717-24-000097","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000097/form4.xml","form_type":"4"}},{"id":1612461,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":90378,"kind":"person","name":"Nielsen Jack","position":1,"cik":"0001602402","reported_name":"Nielsen Jack","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:30:38.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":4411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":4411,"derivative":{"exercise_price":0.96,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":4411},"source":{"system":"sec-edgar","filing":"0001610717-24-000096","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000096/form4.xml","form_type":"4"}},{"id":1612460,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":90378,"kind":"person","name":"Nielsen Jack","position":1,"cik":"0001602402","reported_name":"Nielsen Jack","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:30:38.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":26.58,"exercise_date":"2022-06-17","expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000096","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000096/form4.xml","form_type":"4"}},{"id":1612459,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:29:47.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":4411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":4411,"derivative":{"exercise_price":0.96,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":4411},"source":{"system":"sec-edgar","filing":"0001610717-24-000095","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000095/form4.xml","form_type":"4"}},{"id":1612458,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:29:47.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":26.58,"exercise_date":"2022-06-17","expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000095","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000095/form4.xml","form_type":"4"}},{"id":1612457,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34837,"kind":"person","name":"Martell Bridget A","position":1,"cik":"0001629627","reported_name":"Martell Bridget A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:29:13.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":8823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on November 16, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":8823,"derivative":{"exercise_price":0.96,"expiration_date":"2031-11-16","underlying":"Common Stock","underlying_shares":8823},"source":{"system":"sec-edgar","filing":"0001610717-24-000094","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000094/form4.xml","form_type":"4"}},{"id":1612456,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34837,"kind":"person","name":"Martell Bridget A","position":1,"cik":"0001629627","reported_name":"Martell Bridget A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:29:13.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on November 16, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":16.52,"exercise_date":"2021-12-16","expiration_date":"2031-11-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001610717-24-000094","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000094/form4.xml","form_type":"4"}},{"id":1612706,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":16428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":16428,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":16428},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612705,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":65713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date."}],"balance_after":65713,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":65713},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612704,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":75183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 255,626 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 75,183 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":75183,"derivative":{"exercise_price":0.96,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":75183},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612703,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2025-02-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612702,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2022-03-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":92000},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1612701,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T17:33:26.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":255626,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 255,626 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 75,183 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":16.18,"exercise_date":"2021-01-01","expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":255626},"source":{"system":"sec-edgar","filing":"0001610717-24-000100","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071724000100/form4.xml","form_type":"4"}},{"id":1754336,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrant (Right to Buy)","published_at":"2023-10-27T20:15:41.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":3966800,"price":0.125,"value":495850.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":3966800,"derivative":{"exercise_price":0.7568,"exercise_date":"2023-10-25","expiration_date":"2030-10-25","underlying":"Common Stock","underlying_shares":3966800},"source":{"system":"sec-edgar","filing":"0001610717-23-000320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000320/form4.xml","form_type":"4"}},{"id":1754335,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-10-27T20:15:41.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":7933601,"price":0.7568,"value":6004149.2368,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":11025941,"source":{"system":"sec-edgar","filing":"0001610717-23-000320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000320/form4.xml","form_type":"4"}},{"id":1754334,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2023-10-27T20:14:22.000Z","date":"2023-10-25","kind":"grant","planned":false,"acquired":true,"shares":305138,"price":0.125,"value":38142.25,"ownership":{"direct":true},"balance_after":305138,"derivative":{"exercise_price":0.7568,"exercise_date":"2023-10-25","expiration_date":"2030-10-25","underlying":"Common Stock","underlying_shares":305138},"source":{"system":"sec-edgar","filing":"0001610717-23-000319","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000319/form4.xml","form_type":"4"}},{"id":1754333,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-27T20:14:22.000Z","date":"2023-10-25","kind":"grant","planned":false,"acquired":true,"shares":610277,"price":0.7568,"value":461857.6336,"ownership":{"direct":true},"balance_after":1847575,"source":{"system":"sec-edgar","filing":"0001610717-23-000319","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000319/form4.xml","form_type":"4"}},{"id":1754332,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Warrant (Right to Buy)","published_at":"2023-10-27T20:13:06.000Z","date":"2023-10-25","kind":"grant","planned":false,"acquired":true,"shares":91541,"price":0.125,"value":11442.625,"ownership":{"direct":true},"balance_after":91541,"derivative":{"exercise_price":0.7568,"exercise_date":"2023-10-25","expiration_date":"2030-10-25","underlying":"Common Stock","underlying_shares":91541},"source":{"system":"sec-edgar","filing":"0001610717-23-000318","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000318/form4.xml","form_type":"4"}},{"id":1754331,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-10-27T20:13:06.000Z","date":"2023-10-25","kind":"grant","planned":false,"acquired":true,"shares":183083,"price":0.7568,"value":138557.2144,"ownership":{"direct":true},"balance_after":183083,"source":{"system":"sec-edgar","filing":"0001610717-23-000318","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000318/form4.xml","form_type":"4"}},{"id":1783009,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T20:07:46.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":48000,"derivative":{"exercise_price":0.84,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001610717-23-000276","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000276/form4.xml","form_type":"4"}},{"id":1783008,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T20:07:09.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":48000,"derivative":{"exercise_price":0.84,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001610717-23-000275","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000275/form4.xml","form_type":"4"}},{"id":1783007,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T20:06:02.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":48000,"derivative":{"exercise_price":0.84,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001610717-23-000274","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000274/form4.xml","form_type":"4"}},{"id":1783006,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T20:05:19.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":150000,"derivative":{"exercise_price":0.84,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001610717-23-000273","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000273/form4.xml","form_type":"4"}},{"id":1783144,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T16:08:45.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":48000,"derivative":{"exercise_price":0.84,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001610717-23-000277","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000161071723000277/form4.xml","form_type":"4"}},{"id":1824892,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34837,"kind":"person","name":"Martell Bridget A","position":1,"cik":"0001629627","reported_name":"Martell Bridget A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-22T01:06:01.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":1,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-23-000217","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000217/form4.xml","form_type":"4"}},{"id":1824891,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":90378,"kind":"person","name":"Nielsen Jack","position":1,"cik":"0001602402","reported_name":"Nielsen Jack","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-21T23:23:56.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":1,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-23-000216","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000216/form4.xml","form_type":"4"}},{"id":1824907,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-21T20:13:55.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":1,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-23-000213","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813780/000161071723000213/form4.xml","form_type":"4"}},{"id":1824890,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34836,"kind":"person","name":"Scopa James Paul","position":1,"cik":"0001356950","reported_name":"Scopa James Paul","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-21T20:11:17.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":1,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-23-000212","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000212/form4.xml","form_type":"4"}},{"id":1824889,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-21T20:10:20.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":1,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-23-000210","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000210/form4.xml","form_type":"4"}},{"id":1947236,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T20:11:38.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":78750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":78750,"derivative":{"exercise_price":1.34,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":78750},"source":{"system":"sec-edgar","filing":"0001567619-23-005256","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761923005256/doc1.xml","form_type":"4"}},{"id":1947235,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T20:11:17.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":78750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":78750,"derivative":{"exercise_price":1.34,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":78750},"source":{"system":"sec-edgar","filing":"0001567619-23-005255","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761923005255/doc1.xml","form_type":"4"}},{"id":1947234,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T20:10:54.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":78750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":78750,"derivative":{"exercise_price":1.34,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":78750},"source":{"system":"sec-edgar","filing":"0001567619-23-005254","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761923005254/doc1.xml","form_type":"4"}},{"id":1947233,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":115425,"kind":"person","name":"Beigelman Leonid","position":1,"cik":"0001824721","reported_name":"Beigelman Leonid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T20:10:27.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":169500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":169500,"derivative":{"exercise_price":1.34,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":169500},"source":{"system":"sec-edgar","filing":"0001567619-23-005252","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761923005252/doc1.xml","form_type":"4"}},{"id":1947232,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T20:09:57.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":242500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":242500,"derivative":{"exercise_price":1.34,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":242500},"source":{"system":"sec-edgar","filing":"0001567619-23-005251","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761923005251/doc1.xml","form_type":"4"}},{"id":1947672,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T16:12:14.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.34,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001567619-23-005257","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000156761923005257/doc1.xml","form_type":"4"}},{"id":2209239,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":109794,"kind":"person","name":"Quan Lucinda Y.","position":1,"cik":"0001824711","reported_name":"Quan Lucinda Y.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-11T20:15:13.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":52500,"derivative":{"exercise_price":1.41,"expiration_date":"2032-07-07","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001567619-22-013869","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013869/doc1.xml","form_type":"4"}},{"id":2209240,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-11T20:14:25.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":52500,"derivative":{"exercise_price":1.41,"expiration_date":"2032-07-07","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001567619-22-013868","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013868/doc1.xml","form_type":"4"}},{"id":2209238,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":115425,"kind":"person","name":"Beigelman Leonid","position":1,"cik":"0001824721","reported_name":"Beigelman Leonid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-11T20:13:46.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":113000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":113000,"derivative":{"exercise_price":1.41,"expiration_date":"2032-07-07","underlying":"Common Stock","underlying_shares":113000},"source":{"system":"sec-edgar","filing":"0001567619-22-013867","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013867/doc1.xml","form_type":"4"}},{"id":2209237,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-11T20:13:10.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":161700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":161700,"derivative":{"exercise_price":1.41,"expiration_date":"2032-07-07","underlying":"Common Stock","underlying_shares":161700},"source":{"system":"sec-edgar","filing":"0001567619-22-013866","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013866/doc1.xml","form_type":"4"}},{"id":2209235,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61517,"kind":"person","name":"Symons Julian A.","position":1,"cik":"0001824727","reported_name":"Symons Julian A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-11T20:12:24.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2032-07-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001567619-22-013865","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013865/doc1.xml","form_type":"4"}},{"id":2209292,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":93577,"kind":"person","name":"McClure Matthew W.","position":1,"cik":"0001927121","reported_name":"McClure Matthew W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-11T16:15:52.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":46000,"derivative":{"exercise_price":1.41,"expiration_date":"2032-07-07","underlying":"Common Stock","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0001567619-22-013870","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1927121/000156761922013870/doc1.xml","form_type":"4"}},{"id":2221263,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":113035,"kind":"person","name":"Woiwode Thomas","position":1,"cik":"0001619294","reported_name":"Woiwode Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T20:14:41.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.34,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013392","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013392/doc1.xml","form_type":"4"}},{"id":2221278,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":34844,"kind":"person","name":"Hirth Peter","position":1,"cik":"0001813780","reported_name":"Hirth Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T20:14:08.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.34,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013391","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813780/000156761922013391/doc1.xml","form_type":"4"}}],"next_cursor":"2022-06-27T20:14:08.000000Z,2221278"}